Bank of America’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-40
Closed -$18 8618
2022
Q4
$18 Buy
+40
New +$17 ﹤0.01% 8006
2022
Q2
Sell
-263,340
Closed -$161K 8682
2022
Q1
$161K Buy
263,340
+24,964
+10% +$13.1K ﹤0.01% 6599
2021
Q4
$161K Buy
238,376
+167,072
+234% +$298K ﹤0.01% 6620
2021
Q3
$244K Buy
71,304
+36,532
+105% +$114K ﹤0.01% 6175
2021
Q2
$132K Buy
34,772
+10,200
+42% +$42.2K ﹤0.01% 6356
2021
Q1
$153K Buy
24,572
+11,182
+84% +$99.1K ﹤0.01% 6205
2020
Q4
$105K Buy
+13,390
New +$123K ﹤0.01% 5960

Other funds holding MTCR

Bank of America's MTCR Position: Q1 2023 in Review

Bank of America sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 40 shares — an estimated $18 sold.

Bank of America first reported a position in MTCR in Q4 2020 and held it in 7 quarters. The position peaked at $244K in Q3 2021. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

  • Bank of America reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Bank of America sold 40 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $18.
  • Bank of America first reported a position in Metacrine, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
  • Bank of America's Metacrine, Inc. Common Stock position peaked at $244K in Q3 2021.
  • 5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Bank of America's 13F filing for Q1 2023, filed 12 May 2023.